Summary
Pneumonia is a respiratory infection characterized by inflammation of the alveolar space and/or the interstitial tissue of the lungs. In industrialized nations, it is the leading infectious cause of death. Pneumonia is most commonly transmitted via aspiration of airborne pathogens (primarily bacteria, but also viruses and fungi) but may also result from the aspiration of stomach contents. The most likely causal pathogens can be narrowed down based on patient age, immune status, and where the infection was acquired (community-acquired or hospital-acquired). Pneumonia is classified based on clinical features as either typical and atypical; each type has its own spectrum of commonly associated pathogens. Typical pneumonia manifests with sudden onset of malaise, fever, and a productive cough. On auscultation, crackles and bronchial breath sounds are audible. Atypical pneumonia manifests with gradual onset of unproductive cough, dyspnea, and extrapulmonary manifestations. Auscultation is usually unremarkable. Some patients may present with elements of both types. Diagnostics include blood tests for inflammatory parameters and pathogen detection in blood, urine, or sputum samples. Chest x-ray in cases of typical pneumonia shows opacity restricted to one lobe, while x-ray in atypical pneumonia may show diffuse, often subtle infiltrates. Together with the characteristic clinical features, newly developed pulmonary infiltrate on chest x-ray confirms the diagnosis. Management consists of empiric antibiotic treatment and supportive measures (e.g., oxygen administration, antipyretics).
For specific information on the diagnosis and management of pneumonia in pediatric patients, see “Pneumonia in children.”
Etiology
Pathogens
Pneumonia pathogens according to the source of infection | |
---|---|
Type of pneumonia | Common pathogens |
Community-acquired pneumonia |
|
Hospital-acquired pneumonia |
|
For atypical pneumonia bacterial causes, remember the mnemonic: Atypically, Legions of Clams Mind their P's and Q's!
• Legionella pneumophila
• Chlamydophila pneumoniae
• Mycoplasma pneumoniae
• Psittacosis (Chlamydophila psittaci)
• Q fever (Coxiella burnetii)
Pneumonia pathogens according to location | |
---|---|
Type of pneumonia | Common pathogens |
Lobar pneumonia |
|
Bronchopneumonia | |
Interstitial pneumonia |
|
Cryptogenic organizing pneumonia |
|
Pneumonia pathogens according to affected population | |
---|---|
Type of pneumonia | Common pathogens |
Pneumonia in immunocompromised patients | |
Pneumonia in newborns | |
Pneumonia in children (4 weeks –18 years) |
|
Pneumonia in young adults (18–40 years) | |
Pneumonia in adults (40–65 years) | |
Pneumonia in elderly individuals |
|
Recurrent pneumonia |
|
“Track my respiration: chlassic strep formation”: C. trachomatis, Mycoplasma, Respiratory syncytial virus, Chlamydia pneumoniae, and Streptococcus pneumoniae are the most common causative agents of pneumonia in children.
Risk factors [7]
- Old age and immobility of any cause
-
Chronic diseases
- Preexisting cardiopulmonary conditions (e.g., bronchial asthma, COPD, heart failure)
- Acquired or congenital abnormalities of the airways (e.g., bronchiectasis, space-occupying lesions, cystic fibrosis)
- Immunosuppression
- Impaired airway protection
-
Environmental factors
- Crowded living conditions (e.g., prisons, homeless shelters)
- Toxins (e.g., solvents, gasoline)
- Endemic exposures (e.g., areas of high Coccidioides and Histoplasma endemicity)
- Contaminated water systems (e.g., in hotels, on cruise ships)
- Zoonotic exposures (e.g., birds, farm animals)
-
Cryptogenic organizing pneumonia
- Specific medications; (e.g., amiodarone, bleomycin) [8]
- Chronic inflammatory disorders (e.g., rheumatoid arthritis)
- Surgical procedures
Bear in mind immune status and potential exposures when considering potential pathogens in patients with suspected pneumonia.
Consider aspiration pneumonia in patients with altered mental status or other risk factors for aspiration.
Classification
Pneumonia can be classified according to etiology, location acquired, clinical features, and the area of the lung affected by the pathology.
Etiology
- Primary pneumonia: no apparent preexisting conditions that may predispose to pneumonia
-
Secondary pneumonia
- Bronchial asthma, COPD, heart failure, cystic fibrosis
- Viral upper respiratory tract infections with bacterial superinfection
- Anatomical abnormalities such as tubercular caverns, bronchial tumors, or stenosis (postobstructive pneumonia) [9]
- Aspiration pneumonia
Location acquired
- Community-acquired pneumonia (CAP): pneumonia that is acquired outside of a healthcare establishment
-
Hospital-acquired pneumonia (HAP): nosocomial pneumonia, with onset > 48 hours after admission
- Ventilator-associated pneumonia (VAP): pneumonia occurring in patients who are on mechanical ventilation breathing machines in hospitals (typically in the intensive care unit)
- Healthcare-associated pneumonia (HCAP): pneumonia that is acquired in healthcare facilities (e.g., hospital, nursing homes, hemodialysis centers, and outpatient clinics); this terminology is no longer recommended but is included for historical purposes. [10][11]
Clinical features
-
Typical pneumonia
- Pneumonia featuring classic symptoms (typical findings on auscultation and percussion)
- Manifests as lobar pneumonia or bronchopneumonia
-
Atypical pneumonia
- Pneumonia with less distinct classical symptoms and often unremarkable findings on auscultation and percussion
- Manifests as interstitial pneumonia
Area of lung affected by the pathology
- Lobar pneumonia: pneumonia affecting one lobe of a lung
- Bronchial pneumonia: pneumonia affecting the tissue around the bronchi and/or bronchioles
- Interstitial pneumonia: pneumonia affecting the tissue between the alveoli
- Cryptogenic organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia): a noninfectious pneumonia of unknown etiology characterized by the involvement of the bronchioles, alveoli, and surrounding tissue
Pathophysiology
Routes of infection
- Most common: microaspiration (droplet infection) of airborne pathogens or oropharyngeal secretions
- Aspiration of gastric acid (aspiration pneumonitis) , food, or liquids
- Hematogenous dissemination (rare)
Pathogenesis
- Failure of protective pulmonary mechanisms; (e.g., cough reflex, mucociliary clearance , alveolar macrophages )
- Infiltration of the pulmonary parenchyma by the pathogen → interstitial and alveolar inflammation
- Impaired alveolar ventilation → ventilation/perfusion (V/Q) mismatch with intrapulmonary shunting (right to left)
-
Hypoxia due to increased alveolar-arterial oxygen gradient
- Hypoxia is worsened when the affected lung is in the dependent position, as perfusion to the dependent lung is better compared to the nondependent lung.
- In the case of a large unilateral pulmonary abscess, it may be helpful to position the patient so that the affected lung is in the dependent position in order to prevent the pus from filling the unaffected lung.
Pattern of involvement
-
Lobar pneumonia
- Classic (typical) pneumonia of an entire lobe; primarily caused by pneumococci
- Characterized by inflammatory intra-alveolar exudate, resulting in consolidation
- Can involve the entire lobe or the whole lung
Stages of lobar pneumonia | ||
---|---|---|
Stages | Macroscopic findings | Microscopic findings |
Congestion (day 1–2) |
|
|
Red hepatization (day 3–4) |
|
|
Gray hepatization (day 5–7) |
|
|
Resolution (day 8 to week 4) |
|
|
-
Bronchopneumonia: mostly commonly a descending infection that affects the bronchioles and adjacent alveoli
- Primarily caused by pneumococci and/or other streptococci
- Characterized by acute inflammatory infiltrates that fill the bronchioles and the adjacent alveoli (patchy distribution)
- Usually involves the lower lobes or right middle lobe and affects ≥ 1 lobe
- Manifests as typical pneumonia
- Necrotizing bronchopneumonia and pneumatocele are caused by Staphylococcus aureus and are often preceded by an influenza infection. [12]
-
Interstitial pneumonia: interstitial inflammation, typically caused by Mycoplasma and viral infections
- Characterized by a diffuse patchy inflammation that mainly involves the alveolar interstitial cells
- Bilateral multifocal opacities are classically found on chest x-ray.
- Manifests as atypical pneumonia
- Often has an indolent course (walking pneumonia)
- Miliary pneumonia: multiple small infiltrations caused by hematogenous dissemination (e.g., of tuberculosis)
- Cryptogenic organizing pneumonia: characterized by inflammation of the bronchioles and surrounding structures
Clinical features
Typical pneumonia
Typical pneumonia is characterized by a sudden onset of symptoms caused by lobar infiltration.
- Severe malaise
- High fever and chills
-
Productive cough with purulent sputum (yellow-greenish)
- Crackles and bronchial breath sounds on auscultation
- Decreased breath sounds
- Enhanced bronchophony, egophony, and tactile fremitus
- Dullness on percussion
- Tachypnea and dyspnea (nasal flaring, thoracic retractions)
- Pleuritic chest pain when breathing, often accompanying pleural effusion
- Pain that radiates to the abdomen and epigastric region (particularly in children; see also “Pneumonia in children”)
Suspect bacterial pneumonia in immunocompromised patients with acute high fever and pleural effusion.
Atypical pneumonia
Atypical pneumonia typically has an indolent course (slow onset) and commonly manifests with extrapulmonary symptoms.
- Nonproductive, dry cough
- Dyspnea
- Auscultation often unremarkable
- Common extrapulmonary features include fatigue, headaches, sore throat, myalgias, and malaise.
This classification does not have a major impact on patient management because it is not always possible to clearly distinguish between typical and atypical pneumonia.
Diagnostics
Pneumonia is a clinical diagnosis based on history, physical examination, laboratory findings, and CXR findings. Consider microbiological studies and advanced diagnostics based on patient history, comorbidities, severity, and entity of pneumonia. [13]
In ambulatory settings, the combination of normal vital signs and an unremarkable lung examination indicates a very low likelihood of CAP. [14][15]
Laboratory studies
Routine
- CBC, inflammatory markers: ↑ CRP, ↑ ESR, leukocytosis
-
↑ Serum procalcitonin (PCT): Procalcitonin is an acute phase reactant that can help to diagnose bacterial lower respiratory tract infections. ; [11]
- PCT can be used to guide antibiotic treatment but should not be used to decide if antibiotic therapy is necessary on its own. [11][16][17]
- PCT levels ≥ 0.25 mcg/L correlate with an increased probability of a bacterial infection.
-
Low PCT level after 2–3 days of antibiotic therapy can help facilitate the decision to discontinue antibiotics. [17]
- Decrease of PCT to ≤ 80% of peak level
- Decrease of PCT to < 0.25 mcg/L
- ABG: ↓ PaO2 [13]
- BMP, LFTs
Do not rely on laboratory markers like CRP or procalcitonin to determine the need for antibiotic therapy. [11][18]
Microbiological studies
Indication | Microbiological studies to consider [10][11][13] |
---|---|
Any admitted patient | |
Any patient being treated empirically for MRSA or P. aeruginosa |
|
Severe CAP |
|
Influenza season | |
|
In pandemic or epidemic settings, rule out the prevalent respiratory pathogen (e.g., COVID-19) in all patients with suspected pneumonia. [19]
Avoid routine blood cultures and sputum Gram stain in patients with CAP, except if severe or there is concern for MRSA or Pseudomonas infection. [11]
Imaging
Chest x-ray (posteroanterior and lateral)
- Indications: all patients suspected of having pneumonia
-
X-ray findings in pneumonia
-
Lobar pneumonia
- Opacity of one or more pulmonary lobes
- Presence of air bronchograms: appearance of translucent bronchi inside opaque areas of alveolar consolidation
-
Bronchopneumonia
- Poorly defined patchy infiltrates scattered throughout the lungs
- Presence of air bronchograms
-
Atypical or interstitial pneumonia
- Diffuse reticular opacity
- Absent (or minimal) consolidation
- Parapneumonic effusion
-
Lobar pneumonia
A new pulmonary infiltrate on chest x-ray in a patient with classic symptoms of pneumonia confirms the diagnosis.
Typical pneumonia usually appears as lobar pneumonia on x-ray, while atypical pneumonia tends to appear as interstitial pneumonia. However, the underlying pathogen cannot be conclusively identified based on imaging results alone.
Consider chest CT or empiric treatment if clinical suspicion for CAP remains high despite a negative CXR, as the initial CXR may be falsely negative. [20][21]
Chest CT (usually without contrast)
-
Indications
- Inconclusive chest x-ray
- Recurrent pneumonia
- Poor response to treatment
- Advantages: more reliable evaluation of circumscribed opacities, pleural empyema, or sites of consolidation
-
Findings: [22]
- Localized areas of consolidation (hyperdense)
- Air bronchograms
- Ground-glass opacities
-
Pleural effusion/empyema
- Hyperdense fluid collection
- Split pleura sign
- Nodules
- Large (e.g., in tuberculosis or fungal pneumonia)
- Peribronchial (e.g., bronchopneumonia)
- Disseminated (e.g., septic emboli or varicella-zoster pneumonia)
CT is more sensitive and specific than CXR for the diagnosis of pneumonia.
Lung ultrasound in pneumonia
Point-of-care ultrasound (POCUS) has high sensitivity and specificity for the diagnosis of pneumonia. [23][24]
-
Indications
- Evaluation of suspected pneumonia
- Assessment of undifferentiated dyspnea [25]
-
Characteristic findings [26][27]
- Consolidation
- Irregular and serrated lung margins
- Air bronchograms
- Unilateral B-lines
- Pleural effusion
In the emergency department, consider POCUS to quickly confirm pneumonia and assess for other causes of dyspnea.
Advanced diagnostics for pneumonia
Bronchoscopy
-
Indications
- Suspected mass (e.g., recurrent pneumonia)
- Need for pathohistological diagnosis (e.g., biopsy of a central mass discovered on CT)
- Inconclusive results on CT
- Poor response to treatment
Diagnostic thoracentesis
- Indications: consider if pleural effusion > 10 mm is present to evaluate for pleural empyema [13][28]
- Findings: See “Diagnostics” and “Parapneumonic effusion” in “Pleural effusion”.
- Consider therapeutic thoracentesis in large effusions (≥ half of the hemithorax) or if the effusion is suspected of causing dyspnea [28]
- Consider tube thoracostomy if pleural empyema (e.g., echogenic debris on lung ultrasound) or complicated effusion (e.g.,pH < 7.20, glucose < 60 mg/dL, LDH above three times the upper limit of serum LDH, positive culture) is suspected [28]
Treatment
Approach
- Evaluate all patients for hypoxemia and/or sepsis and manage as indicated.
- Assess the need for hospitalization with the CURB-65 score or the pneumonia severity index (PSI/PORT score).
- Determine the appropriate level of care using clinical judgment and the IDSA/ATS criteria for severe CAP.
- Begin empiric antibiotic therapy based on severity and patient risk factors (e.g., VAP vs. CAP).
- Provide supportive care.
- Re-evaluate therapy after 48 hours (earlier if the patient's condition deteriorates or new information becomes available).
Initial stabilization [29][30]
- Identification and management of sepsis
- Fluid resuscitation and management of septic shock as needed
- Respiratory support as needed
Criteria for hospitalization [11][18]
Every patient should be assessed individually and clinical judgment is the most important factor. The pneumonia severity index (PSI) and the CURB-65 score are tools that can help to determine whether to admit a patient.
-
CURB-65 score [31]
- Confusion (disorientation, impaired consciousness)
- Serum Urea > 7 mmol/L (42 mg/dL)
- Respiratory rate ≥ 30/min
- Blood pressure: systolic BP ≤ 90 mm Hg or diastolic BP ≤ 60 mm Hg
- Age ≥ 65 years
-
Interpretation
- Each finding is assigned 1 point.
- CURB-65 score 0 or 1: The patient may be treated as an outpatient.
- CURB-65 score ≥ 2: Hospitalization is indicated.
- CURB-65 score ≥ 3: Consider ICU level of care.
-
CRB-65 score (if serum urea is not known or unavailable)
- CRB-65 score of 0: The patient may be treated as an outpatient.
- CRB-65 score of ≥ 1: Hospitalization is recommended.
-
Pneumonia severity index (PSI/PORT score) [32]
- Patients are assigned to one of five risk classes based on a more complex point system than in CURB-65.
- Points are distributed based on patient age, comorbidities, and lab results.
The CURB-65 score and PSI are tools for evaluating the risk of mortality. They have not been validated for determining the necessity for ICU admission.
Criteria for ICU admission [11][18]
- The decision of whether to admit a patient to the ICU should be based on clinical judgment.
- The IDSA/ATS criteria for severe CAP can be used to help triage patients with CAP and guide empiric antibiotic treatment decisions. [11]
IDSA/ATS criteria for severe CAP [11] | |
---|---|
Major criteria | |
Minor criteria |
|
Interpretation
|
Empiric antibiotic therapy for community-acquired pneumonia [11][33]
Outpatient
Empiric antibiotic therapy for community-acquired pneumonia in an outpatient setting | |
---|---|
Patient profile | Recommended empiric antibiotic regimen [11] |
Previously healthy patients without comorbidities or risk factors for resistant pathogens |
|
Patients with comorbidities or risk factors for resistant pathogens |
|
-
Duration of treatment
- 5 days of therapy is usually sufficient for CAP that is treated in the outpatient setting.
- Any patient being treated in a primary care setting should be re-examined after 48–72 hours to evaluate the efficacy of the prescribed antibiotic.
- Additional considerations: Knowing local resistance patterns of S. pneumoniae to macrolides is critical when deciding on an empiric antibiotic regimen.
Inpatient
Empiric antibiotic therapy for community-acquired pneumonia in an inpatient setting | |
---|---|
Patient profile | Recommended empiric antibiotic regimen [11] |
Nonsevere CAP/non-ICU treatment
|
|
|
|
Risk factors for Pseudomonas aeruginosa
|
|
|
|
-
Duration of therapy
- 5–7 days is usually sufficient.
- Consider longer courses in patients with one of the following:
- Patient not responding to treatment
- Suspected or concern for MRSA or P. aeruginosa infection
- Concurrent meningitis
- Unusual pathogens (e.g., Burkholderia pseudomallei, fungal infection)
-
Additional considerations
- If aztreonam is used instead of a β-lactam antibiotic (e.g., for penicillin allergy), the addition of MSSA coverage (e.g., a fluoroquinolone) is necessary.
- Anaerobic coverage is not routinely recommended for suspected aspiration pneumonia (unless lung abscess or empyema is suspected). [11]
- Corticosteroids are not routinely recommended as adjunct therapy. [11]
If aztreonam is used as an alternative to other β-lactam antibiotics, additional coverage for MSSA must be included (e.g., a fluoroquinolone).
Empiric antibiotic therapy for hospital-acquired pneumonia [10]
Empiric antibiotic therapy for hospital-acquired pneumonia | |
---|---|
Patient profile | Recommended empiric antibiotic regimen [10] |
Patients not at high risk for mortality and without risk factors for MRSA infection |
|
Patients not at high risk for mortality but with risk factors for MRSA infection |
|
Patients at high risk for mortality Patients with structural lung disease (e.g., cystic fibrosis, bronchiectasis) |
|
-
Duration of treatment
- Empiric antibiotic therapy should be narrowed and/or de-escalated as soon as feasible.
- Seven days of therapy are usually sufficient. [10]
- Additional considerations: Resistance patterns can vary widely; local antibiograms should be considered when starting empiric treatment.
Patients with structural lung disease and/or at high risk for mortality should receive double antipseudomonal coverage!
Empiric antibiotic therapy for ventilator-associated pneumonia [10]
-
Recommended combination therapy
- An antipneumococcal, antipseudomonal β-lactam
- PLUS one of the following antibiotics with MRSA activity:
- PLUS one of the following:
- Duration of treatment: Seven days of therapy are usually sufficient. [10]
-
Additional considerations:
- Risk factors for multi-drug resistant organisms (e.g., presence of structural lung disease, recent IV antibiotic therapy, local resistance patterns) should be considered when deciding on an empiric regimen
- Empiric antibiotic therapy for ventilator-associated tracheobronchitis is not routinely recommended. [10]
Supportive therapy for pneumonia
- Sufficient rest (not absolute bed rest) and physical therapy
- Hydration with PO or IV fluids, supplemental oxygen as needed
- Incentive spirometer
- Antipyretics, analgesics as needed (e.g., acetaminophen )
- Expectorants and mucolytics [34]
- Antitussives (e.g., codeine )
Acute management checklist
- Calculate the CURB-65 score and/or PSI/PORT score to identify patients who would benefit from admission.
- Assess severity of CAP with the IDSA/ATS criteria for severe CAP.
- Order microbiological workup as indicated by patient severity and risk factors.
- Community-acquired pneumonia: Start empiric antibiotics for CAP.
- Hospital-acquired pneumonia: Start empiric antibiotics for HAP.
- Ventilator-associated pneumonia: Start empiric antibiotics for VAP.
- Evaluate and treat sepsis if present (see sepsis).
- Administer supplemental O2 if patient is hypoxemic.
- Consider advanced diagnostic evaluation. [33]
- Provide supportive care for pneumonia (e.g., antipyretics, , IV fluids).
- Continuous pulse oximetry
- Trend inflammatory markers, procalcitonin.
- Narrow antibiotic therapy as soon as feasible.
Pathogen-specific pneumonia
Mycoplasma pneumonia [35]
-
Epidemiology
- One of the most common causes of atypical pneumonia
- More common in school-aged children and adolescents
- Outbreaks most commonly occur in schools, colleges, prisons, and military facilities.
-
Clinical features
- Generalized papular rash
- Erythema multiforme
- See “Atypical pneumonia”.
-
Diagnostics
- Subclinical hemolytic anemia: associated with elevated cold agglutinin titers (IgM)
- Interstitial pneumonia; , often with a reticulonodular pattern on chest x-ray
- Chest x-ray can show extensive pulmonary involvement in patients with mild pneumonia.
-
Treatment
- A macrolide, doxycycline, or fluoroquinolones
- Beta-lactam antibiotics are not effective
- See “Empiric antibiotics for CAP” for dosages and duration of treatment.
Other types of pathogen-specific pneumonia
- Legionnaire disease
- Pneumocystis pneumonia
- Pseudomonas aeruginosa: causes VAP
- Tuberculosis
- Primary influenza pneumonia
- Various viral infections (e.g., respiratory syncytial virus, hantavirus, adenovirus, CMV, SARS-CoV, SARS-CoV-2)
- Ornithosis
Aspiration pneumonia
Definitions
-
Aspiration
- The inhalation of foreign material into the respiratory tract
- Most commonly occurs after instrumentation of the upper airways or esophagus (e.g., upper GI endoscopy) or secondary to vomiting and regurgitation of gastric contents
- Aspiration pneumonia: a type of pneumonia that occurs as a result of oropharyngeal secretions and/or gastric contents aspiration
-
Aspiration pneumonitis
- Aspiration of gastric acid that initially causes tracheobronchitis, with rapid progression to chemical pneumonitis
- May cause ARDS in extreme cases
Patients may develop aspiration pneumonitis without pneumonia, aspiration pneumonia without pneumonitis, or aspiration pneumonitis complicated by pneumonia. [36]
Etiology
-
Pathogens [11][36]
- Gram-positive and gram-negative aerobic bacteria predominate in community-acquired infections (e.g., S. pneumonia, S. aureus, H. influenza, Enterobacteriaceae).
- Gram-negative bacilli predominate in hospital-acquired infections (e.g., P. aeruginosa, Klebsiella spp.).
- Mixed infections with anaerobic organisms; may occur (e.g., Fusobacterium, Peptostreptococcus, Bacteroides).
-
Risk factors for aspiration (predispose individuals to reduced epiglottic gag reflex and dysphagia)
- Altered consciousness: alcohol, sedation, general anesthesia, stroke
- Apoplexy and neurodegenerative conditions
- Gastroesophageal reflux disease, esophageal motility disorders
- Congenital defects (e.g., tracheoesophageal fistula)
- Use of a nasogastric feeding tube
Aspiration pneumonitis and pneumonia are unusual following aspiration of tube feeds or blood, which are typically high-pH and sterile. [36]
Clinical features [36][37]
- Aspiration pneumonitis
-
Aspiration pneumonia
- Immediate symptoms: often none
- Late symptoms: fever, shortness of breath, cough with foul-smelling sputum
Diagnostics of pulmonary aspiration
Clinical diagnosis supported by characteristic laboratory and imaging findings
- Laboratory and microbiological studies: same as for the diagnosis of pneumonia.
- ABG: e.g., ↓ PaO2
- Imaging: The lung region in which the infiltrates are seen depends on the patient's position on aspiration. [38][39]
- Supine position: superior segment of the right lower lobe (most common site of aspiration)
- Standing/sitting: posterior basal segment of the right lower lobe
- Right lateral decubitus position: posterior segment of the right upper lobe or right middle lobe
The initial CXR may be negative in early aspiration pneumonia. [36]
Treatment of pulmonary aspiration [36]
-
Acute aspiration: airway management and respiratory support
- Immediate oropharyngeal suctioning
- Intubation if there is ongoing risk of aspiration (e.g., post-extubation, ↓ LOC)
- O2 therapy and inhaled bronchodilators as needed
-
Aspiration pneumonitis: typically requires supportive care only
- Antibiotics are usually not required [11]
- Consider empiric antibiotics for patients with any of the following :
-
Aspiration pneumonia: antibiotic therapy following standard pneumonia treatment regimens
- Choose agents based on site of acquisition, illness severity, and risk factors for resistant organisms (see “Empiric antibiotics for CAP“ and “Empiric antibiotics for HAP”).
- Consider coverage for anaerobic bacteria (e.g., with ampicillin-sulbactam, moxifloxacin) in patients with severe periodontal disease, lung abscess, or empyema. [11][36][40]
- All patients: supportive care for pneumonia, monitoring, consider serial imaging.
Aspiration pneumonia requires antibiotic therapy while aspiration pneumonitis typically self-resolves within 24–48 hours with supportive care alone. [11][41]
Avoid routine anaerobic coverage for aspiration pneumonia without lung abscess, empyema, or severe periodontal disease. [40]
Complications
Prevention [36]
- Treatment of underlying causes to reduce the risk of aspiration
- NPO status prior to elective procedures with general anesthesia
- Formal swallowing evaluation when clinically appropriate
- Aspiration precautions for patients with risk factors for aspiration
Complications
-
Parapneumonic pleuritis
- Fibrinous pleuritis: inflammation → increased vessel permeability → fibrin-rich exudate deposited on the serosal surface of the pleura → pleuritic chest pain and friction rub
- Analgesics can be used for the relief of symptoms.
- Parapneumonic pleural effusion (common)
- Pleural empyema
- Lung abscess
- ARDS
- Respiratory failure
- Sepsis
We list the most important complications. The selection is not exhaustive.
Prognosis
- Mortality increases with age.
- The mortality risk can be evaluated with the CURB-65 score. [42]
- Score 0: ∼ 1%
- Score 1–2: ∼ 10%
- Score 3: ∼ 14%
- Score 4: ∼ 40%
- HAP is associated with a mortality rate of > 20%.
Prevention
- Immunization (see “ACIP immunization schedule” for information on doses and intervals)
- Smoking cessation
Related One-Minute Telegram
- One-Minute Telegram 87-2023-2/3: Breathe easier: a breakthrough in preventing ventilator-associated pneumonia
- One-Minute Telegram 72-2023-1/3: An infusion of hope for pneumonia survival
- One-Minute Telegram 36-2021-1/3: Can probiotics prevent pneumonia in mechanically ventilated patients?
- One-Minute Telegram 36-2021-2/3: Can point-of-care testing safely reduce the use of antibiotics?
- One-Minute Telegram 14-2020-2/3: Admit patient to home: virtual hospitals for patients with COVID-19
- One-Minute Telegram 13-2020-1/3: Robots vs. residents: who can interpret chest x-rays better?
Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.